Monopar Therapeutics Stock Price on May 15, 2024
| MNPR Stock | USD 24.00 1.82 7.05% |
Below is the normalized historical share price chart for Monopar Therapeutics extending back to December 19, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Monopar Therapeutics stands at 24.00, as last reported on the 23rd of December, with the highest price reaching 27.11 and the lowest price hitting 23.04 during the day.
If you're considering investing in Monopar Stock, it is important to understand the factors that can impact its price. Monopar Therapeutics is out of control given 3 months investment horizon. Monopar Therapeutics has Sharpe Ratio of 0.13, which conveys that the firm had a 0.13% return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 9.6% are justified by taking the suggested risk. Use Monopar Therapeutics Downside Deviation of 12.87, mean deviation of 19.05, and Risk Adjusted Performance of 0.1093 to evaluate company specific risk that cannot be diversified away.
At this time, Monopar Therapeutics' Total Stockholder Equity is relatively stable compared to the past year. As of 12/23/2024, Liabilities And Stockholders Equity is likely to grow to about 12.6 M, while Common Stock Shares Outstanding is likely to drop slightly above 12.7 M. . As of 12/23/2024, Price Earnings To Growth Ratio is likely to grow to 0.10, while Price Earnings Ratio is likely to drop (3.08). Monopar Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 19th of December 2019 | 200 Day MA 7.1167 | 50 Day MA 17.8468 | Beta 1.104 |
Monopar |
Sharpe Ratio = 0.1269
| Best Portfolio | Best Equity | MNPR | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 75.7 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Monopar Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Monopar Therapeutics by adding it to a well-diversified portfolio.
Price Book 27.3343 | Book Value 1.875 | Enterprise Value 128 M | Enterprise Value Ebitda (2.42) | Shares Float 1.6 M |
Related Headline
Acurx Pharmaceuticals Headline on 15th of May 2024
Acurx Pharmaceuticals GAAP EPS of -0.28 misses by 0.04 by seekingalpha.com
Acurx Pharmaceuticals Q1 earnings disappoint with a GAAP EPS of -0.28, missing expectations by 0.04.
Monopar Therapeutics Valuation on May 15, 2024
It is possible to determine the worth of Monopar Therapeutics on a given historical date. On May 15, 2024 Monopar was worth 3.21 at the beginning of the trading date compared to the closed value of 2.99. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Monopar Therapeutics stock. Still, in general, we apply an absolute valuation method to find Monopar Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Monopar Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Monopar Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 3.36 | 3.55 | 3.26 | 3.26 | 12,540 | |
05/15/2024 | 3.21 | 3.35 | 2.83 | 2.99 | 22,087 |
| 3.06 | 3.09 | 3.02 | 3.09 | 6,888 |
| Backtest Monopar Therapeutics | | | Monopar Therapeutics History | | | Monopar Therapeutics Valuation | Previous | Next |
Monopar Therapeutics Trading Date Momentum on May 15, 2024
| On May 16 2024 Monopar Therapeutics was traded for 3.09 at the closing time. The top price for the day was 3.09 and the lowest listed price was 3.02 . The trading volume for the day was 6.9 K. The trading history from May 16, 2024 was a factor to the next trading day price gain. The trading delta at closing time against the next closing price was 3.34% . The trading delta at closing time against the current closing price is 0.67% . |
Monopar Therapeutics Fundamentals Correlations and Trends
By evaluating Monopar Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Monopar Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Monopar financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Monopar Therapeutics Stock history
Monopar Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Monopar is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Monopar Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Monopar Therapeutics stock prices may prove useful in developing a viable investing in Monopar Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 14.5 M | 12.7 M | |
| Net Loss | -8.2 M | -8.6 M |
Monopar Therapeutics Quarterly Net Working Capital |
|
Monopar Therapeutics Stock Technical Analysis
Monopar Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Monopar Therapeutics Period Price Range
Low | December 23, 2024
| High |
0.00 | 0.00 |
Monopar Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Monopar Therapeutics December 23, 2024 Market Strength
Market strength indicators help investors to evaluate how Monopar Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Monopar Therapeutics shares will generate the highest return on investment. By undertsting and applying Monopar Therapeutics stock market strength indicators, traders can identify Monopar Therapeutics entry and exit signals to maximize returns
Monopar Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Monopar Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Monopar Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Monopar to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1093 | |||
| Jensen Alpha | 9.5 | |||
| Total Risk Alpha | 7.31 | |||
| Sortino Ratio | 0.7302 | |||
| Treynor Ratio | (2.58) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.